ReShape Lifesciences Inc. (RSLS)
Largest Insider Buys in Sector
RSLS Stock Price History Chart
RSLS Stock Performance
About ReShape Lifesciences Inc.
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Insider Activity of ReShape Lifesciences Inc.
Over the last 12 months, insiders at ReShape Lifesciences Inc. have bought $26,907 and sold $542 worth of ReShape Lifesciences Inc. stock.
On average, over the past 5 years, insiders at ReShape Lifesciences Inc. have bought $427,875 and sold $4.03M worth of stock each year.
Highest buying activity among insiders over the last 12 months: STANKOVICH THOMAS (Chief Financial Officer) — $26,907.
The last purchase of 17,702 shares for transaction amount of $26,907 was made by STANKOVICH THOMAS (Chief Financial Officer) on 2023‑06‑30.
List of Insider Buy and Sell Transactions, ReShape Lifesciences Inc.
| 2023-10-25 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 131 0.0027% | $0.27 | $35 | -19.84% | |
| 2023-10-11 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 39 0.0026% | $0.93 | $36 | -24.33% | |
| 2023-09-01 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 118 0.0034% | $0.89 | $105 | -76.87% | |
| 2023-08-24 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 39 0.0013% | $1.42 | $55 | -80.85% | |
| 2023-08-04 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 108 0.0036% | $1.43 | $154 | -84.39% | |
| 2023-07-06 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 106 0.0064% | $1.47 | $156 | -83.56% | |
| 2023-06-30 | STANKOVICH THOMAS | Chief Financial Officer | 17,702 1.0643% | $1.52 | $26,907 | -84.06% | ||
| 2023-05-31 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 98 0.0057% | $2.41 | $236 | -89.67% | |
| 2023-04-30 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 96 <0.0001% | $2.36 | $227 | -64.13% | |
| 2023-03-31 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 109 <0.0001% | $2.60 | $283 | -85.51% | |
| 2023-02-28 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 103 <0.0001% | $4.25 | $438 | -77.03% | |
| 2023-02-02 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 157 <0.0001% | $13.29 | $2,087 | -78.25% | |
| 2023-01-24 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 158 <0.0001% | $7.49 | $1,183 | -81.24% | |
| 2022-12-01 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 7,357 0.0335% | $0.15 | $1,112 | -69.81% | |
| 2022-11-28 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 364,756 1.9555% | $0.17 | $61,826 | -68.05% | |
| 2022-11-04 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 8,393 0.0385% | $0.27 | $2,287 | -82.14% | |
| 2022-10-04 | Sale | STANKOVICH THOMAS | CFO | 8,293 0.0337% | $0.28 | $2,329 | ||
| 2022-09-06 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 4,828 0.0219% | $0.39 | $1,883 | -80.26% | |
| 2022-08-05 | Sale | Bandy Barton P. | President and CEO | 11,674 0.0484% | $0.47 | $5,487 | -75.94% | |
| 2022-08-05 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 4,728 0.0196% | $0.47 | $2,222 | -75.94% |
Insider Historical Profitability
| STANKOVICH THOMAS | Chief Financial Officer | 22949 0.0978% | $0.20 | 6 | 29 | <0.0001% |
| SABBY MANAGEMENT, LLC | 10 percent owner | 1192507 5.0838% | $0.20 | 10 | 0 | <0.0001% |
| DOMAIN PARTERS VII L P | 10 percent owner | 813433 3.4678% | $0.20 | 2 | 0 | <0.0001% |
| Bandy Barton P. | President and CEO | 773098 3.2958% | $0.20 | 0 | 12 | |
| INTERWEST PARTNERS X LP | 10 percent owner | 380224 1.6209% | $0.20 | 2 | 0 | <0.0001% |
| GLADNEY DAN W | director | 283922 1.2104% | $0.20 | 0 | 1 | |
| Plovanic William J. | President & CEO | 106806 0.4553% | $0.20 | 3 | 0 | <0.0001% |
| ARMISTICE CAPITAL, LLC | 10 percent owner | 105873 0.4513% | $0.20 | 16 | 3 | +38.61% |
| Rasdal Andrew P | Exec Chairman of the Board | 77892 0.3321% | $0.20 | 1 | 0 | <0.0001% |
| Brister Mark | Chief Technology Officer | 38865 0.1657% | $0.20 | 1 | 0 | <0.0001% |
| Kamdar Kim P. | director | 27148 0.1157% | $0.20 | 3 | 0 | <0.0001% |
| Drake Neil | VP Research and Development | 26850 0.1145% | $0.20 | 1 | 0 | |
| HOWE LESLEY H | director | 19397 0.0827% | $0.20 | 1 | 0 | <0.0001% |
| Stevenson Sharon | director | 18061 0.077% | $0.20 | 1 | 0 | <0.0001% |
| Hussainy Nooshin | VP of Finance | 16340 0.0697% | $0.20 | 1 | 0 | <0.0001% |
| VandenBerg Amy | Chief Clinical & Reg Officer | 11764 0.0502% | $0.20 | 1 | 0 | <0.0001% |
| MacDonald Robert J | Chief Retail Officer | 5245 0.0224% | $0.20 | 1 | 0 | <0.0001% |
| Norwood Matthew | VP of Sales | 1000 0.0043% | $0.20 | 1 | 0 |
Institutional Investor Ownership
No records found… | |||||||